Aarti Drugs Limited has uploaded the audio recording of its quarterly earnings conference call for the quarter ended June 30, 2026 (Q1FY27), to its official website. The company also confirmed that a detailed transcript of the discussion will be shared with stock exchanges and published online in due course. This update follows the earlier intimation of the call scheduled for August 3, 2026.

Call Recording and Transcript Availability

The audio recording is now accessible to investors and analysts via the company’s website at https://www.aartidrugs.com/reports-fillings-concall-recording . The filing, dated August 3, 2026, and signed by Company Secretary & Compliance Officer Rushikesh Vivek Deole, was submitted under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Previous Conference Call Details

The earnings call, held on Monday, August 3, 2026, at 11:00 AM IST, featured senior management discussing financial performance for Q1FY27. Key participants included Joint Managing Director Harshit Savla, Whole Time Director Harit Shah, Chief Finance Officer & COO Adhish Patil, and Managing Director of Pinnacle Life Science Private Limited, Vishwa Savla.

Access Information

Participants could join the call using country-specific dial-in numbers provided by Strategic Growth Advisors Pvt. Ltd. The availability of the recording ensures broader access for stakeholders who were unable to attend the live session.

Aarti Drugs published its audited standalone and consolidated financial results for the quarter ended June 30, 2026 (Q1FY27) in two newspapers on August 2, 2026. The results were published in Financial Express (English) and Pratahkal (Marathi), as required under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This publication ensures wider accessibility of the company’s financial performance to investors and stakeholders across different language preferences.

Publication Details

The financial results were formally submitted to the Listing/Compliance Departments of both BSE Limited and the National Stock Exchange of India Limited on August 3, 2026. The submission was signed by Rushikesh Vivek Deole, Company Secretary & Compliance Officer of Aarti Drugs Limited. The publication serves as a regulatory compliance measure, ensuring that all shareholders have equal access to the company’s financial information.

Financial Results Overview

The published results confirm the previously reported financial performance for Q1FY27. Consolidated revenue stood at ₹703.59 crore, while consolidated profit after tax (PAT) was ₹50.13 crore. Standalone revenue was ₹627.65 crore with a PAT of ₹50.85 crore. These figures align with the earlier disclosures made by the company regarding its strong operational performance in the quarter.

Regulatory Compliance

The results were reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on July 31, 2026. The statutory auditors carried out an audit of the financial results and expressed an unmodified audit opinion. The company has three subsidiaries — Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited, and Pinnacle Chile SpA — along with two step-down subsidiaries, Pharma Go SpA and Tripharma Chile SpA.

What the Numbers Show

The dual-language publication strategy reflects Aarti Drugs’ commitment to inclusive investor communication. By publishing in both English and Marathi, the company ensures that regional investors who may prefer local language media can access critical financial information without barriers. This approach enhances transparency and broadens the reach of the company’s financial disclosures beyond traditional English-speaking investor circles.